Prostate Cancer | Specialty

Novel Prostate Cancer Biomarkers

November 30th 2015

Use of AR-V7 as a Prostate Cancer Biomarker

November 30th 2015

Swedish Biomarker Test STHLM3 Identifies Aggressive Form of Prostate Cancer

November 26th 2015

A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.

Dr. Koo on Degarelix for the Treatment of Prostate Cancer

November 24th 2015

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association, discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

ADT Plus Chemo Ideal for Oligometastatic Prostate Cancer

November 17th 2015

Oligometastatic prostate cancer is optimally treated with the combination of docetaxel and androgen deprivation therapy.

Dr. Michael Morris on Combining and Sequencing Radium-223

November 13th 2015

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Factors Identified for Improved Survival With Radium-223

November 13th 2015

Researchers are starting to understand which patients with castration-resistant prostate cancer (CRPC) may benefit most from treatment with radium-223.

Use of Radium-223 Continues to Evolve in mCRPC

November 12th 2015

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

Dr. Koo Discusses Focal Therapy for Prostate Cancer

November 10th 2015

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

November 10th 2015

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal

November 7th 2015

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Physicians on the Offense: Get Organized to Thrive in This Payment Arena

November 7th 2015

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

Deliver Androgen Blockade at Prostate Cancer Cells to Achieve Castrate Levels

November 6th 2015

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

Dr. Concepcion Discusses Healthcare's Transition Away From Fee-For-Service

November 6th 2015

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

Novel Combinations Hold Promise in Treatment-Resistant mCRPC

November 6th 2015

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

Crawford Questions ADT Standards, Approaches in Prostate Cancer

November 6th 2015

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

Olaparib Demonstrates High Response in mCRPC With DNA-Repair Defects

November 2nd 2015

The PARP inhibitor olaparib had an overall response rate of nearly 90% in a biomarker-defined subgroup of patients with metastatic castration-resistant prostate cancer who had DNA-repair defects.

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

October 30th 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Sartor Discusses Expanded Radium-223 Program, STAMPEDE Data in Prostate Cancer

October 27th 2015

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

Dr. Saad on Next Steps for Radium-223 in mCRPC

October 26th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.